title: Use of steatotic graft in living-donor liver transplantation.
abstract: BACKGROUND
  The degree of fatty infiltration in hepatic grafts is known to be an important risk factor for primary graft nonfunction in cadaveric liver transplantation. However, the effect of hepatic steatosis in living-donor liver transplantation (LDLT) has not yet been well defined. In this study, we evaluated the impact that the degree of hepatic graft steatosis has on the outcome of LDLT.
  
  
  METHODS
  Sixty consecutive donors and recipients who underwent LDLT between October 1996 and August 2001 at Kyushu University Hospital were the subjects of this study. The pathologic findings of the prereperfusion biopsy of the graft were classified into the following three groups according to the degree of macrovesicular steatosis: None (n=23), 0% steatosis; Mild (n=23), 0% to 20% steatosis; and Moderate (n=6), 20% to 50% steatosis. Liver function tests including total bilirubin (at postoperative day [POD] 7), the peak alanine aminotransferase (ALT) and prothrombin time (at POD 3), and both patient and graft survival were compared among the groups. Furthermore, we also compared the donor parameters including the peak ALT and total bilirubin (at POD 3) and the operative time, blood loss, and length of hospital stay after surgery.
  
  
  RESULTS
  The 1-year patient and graft survival were comparable among the groups. The peak ALT was significantly higher in the Moderate group (606+/-641 IU/L) than in the None (290+/-190 IU/L) and Mild (376+/-296 IU/L) groups. Total bilirubin (POD 7) and prothrombin time (POD 3) were comparable among the groups. The donor parameters were comparable among the groups except for the fact that the donor body weight of the Mild and Moderate groups were significantly heavier (P<0.0001) than that of the None group.
  
  
  CONCLUSIONS
  In conclusion, the use of a fatty liver graft up to the moderate level can be justified in LDLT, even though ischemia-reperfusion injury tends to be severe in such grafts.
authors.affiliation: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. ysoejima@surg2.med.kyushu-u.ac.jp.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Soejima
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Shimada
authors.forename: Taketoshi
authors.initials: T
authors.lastname: Suehiro
authors.forename: Keiji
authors.initials: K
authors.lastname: Kishikawa
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Yoshizumi
authors.forename: Koji
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Minagawa
authors.forename: Shoji
authors.initials: S
authors.lastname: Hiroshige
authors.forename: Takahiro
authors.initials: T
authors.lastname: Terashi
authors.forename: Mizuki
authors.initials: M
authors.lastname: Ninomiya
authors.forename: Satoko
authors.initials: S
authors.lastname: Shiotani
authors.forename: Noboru
authors.initials: N
authors.lastname: Harada
authors.forename: Keizo
authors.initials: K
authors.lastname: Sugimachi
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001706:Biopsy; D001835:Body Weight; D002648:Child; D005234:Fatty Liver / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D005260:Female; D006085:Graft Survival; D006801:Humans; D016031:Liver Transplantation / Q000401:mortality*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011517:Prothrombin Time; D012720:Severity of Illness Index
chemical_list: D000410:Alanine Transaminase; D001663:Bilirubin